Literature DB >> 263880

Nafcillin-induced neutropenia in children.

G R Greene, E Cohen.   

Abstract

Neutropenia developed in three pediatric patients treated intravenously with nafcillin. This association has not been, to our knowledge, previously reported in children. One of the patients is the youngest reported who had neutropenia associated with any penicillin; another patient had a prolonged recovery. The literature pertaining to marrow suppression by all penicillins is reviewed. This usually occurs 10 to 25 days after the inception of high-dose intravenous therapy and resolves when the penicillin therapy is discontinued. An absolute neutrophil count of less than 1,000/ml is an indication to change to an antibiotic other than a penicillin. Children receiving intravenous penicillins should have WBC counts with differential analysis two to three times a week.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 263880

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  5 in total

1.  Current antibiotic usage, I: Penicillins, cephalosporins and chloramphenicol.

Authors:  S M Merchant; N P Vithlani
Journal:  Indian J Pediatr       Date:  1986 Jan-Feb       Impact factor: 1.967

2.  Myelosuppression Rates with Administration of Nafcillin with and without Rifampin in Pediatric Patients.

Authors:  Jolly Kuriakose; Michelle Kaplansky; Caroline M Sierra
Journal:  Pediatr Rep       Date:  2022-06-08

3.  Neutropenia after penicillins: toxic or immune-mediated?

Authors:  K A Neftel; M Wälti; H Spengler; A von Felten; S A Weitzman; H Bürgi; A L de Weck
Journal:  Klin Wochenschr       Date:  1981-08-17

4.  Agranulocytosis associated with semisynthetic penicillins and cephalosporins. Report of 7 cases.

Authors:  L Schmid; W Heit; R Flury
Journal:  Blut       Date:  1984-01

5.  Side effects of cloxacillin in infants and children.

Authors:  M A St John; C G Prober
Journal:  Can Med Assoc J       Date:  1981-09-01       Impact factor: 8.262

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.